Inflammation, a silent killer in cancer is not so silent!
- 9 August 2009
- journal article
- editorial
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 9 (4), 347-350
- https://doi.org/10.1016/j.coph.2009.06.018
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Models for prevention and treatment of cancer: Problems vs promisesBiochemical Pharmacology, 2009
- Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term FoeClinical Cancer Research, 2009
- Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targetsTrends in Pharmacological Sciences, 2008
- TNF: A master switch for inflammation to cancerFrontiers in Bioscience-Landmark, 2008
- Epidermal growth factor (EGF) activates nuclear factor-κB through IκBα kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IκBαOncogene, 2007
- Transcription Factor NF‐κB: A Sensor for Smoke and Stress SignalsAnnals of the New York Academy of Sciences, 2005
- Nuclear factor-κBCancer Cell, 2004
- Nuclear factor-κB: a friend or a foe in cancer?Biochemical Pharmacology, 2004
- Cyclooxygenase (COX)-2 Inhibitor Celecoxib Abrogates Activation of Cigarette Smoke-Induced Nuclear Factor (NF)-κB by Suppressing Activation of I-κB α Kinase in Human Non-Small Cell Lung CarcinomaCancer Research, 2004
- Nuclear transcription factor-κB as a target for cancer drug developmentLeukemia, 2002